INTRODUCTION
Recurrent respiratory papillomatosis (RRP) caused by human papillomavirus (HPV) is characterized by proliferation of premalignant squamous papillomas within the respiratory tract. Although over 90% of the cases are associated with low-risk strains (type 6 and 11), the disease has often dramatic presentation due to signifi cant airway obstruction, debilitating frequency of relapses after standard surgery, and unpredictable prognosis. 1, 2 Malignant degeneration to squamous cell carcinoma with very poor prognosis is observed in 3-5% of patients. Extension into the lower airways occurs in approximately 17% of patients. 3, 4 Having in mind that asymptomatic HPV infection is very common among the population, the low incidence of RRP raises the question about the immune mechanisms that might determine the occurrence, relapses, and malignisation. 4 Contemporary CO 2 laser microsurgery is sparing but does not prevent relapses. Multiple combined protocols including antivirals (ribavirin and cidofovir), vitamins and oligoelements, cyclooxygenase-2, ЕGFR or IFNγ have been applicated without defi nitive success. 1 Effi cient control of viral infections comprises imminent NK cell activation; followed by the differentiation of IFNγ producing CD4 (Th1) and CD8 T cell effectors. In addition, regulatory CD4+FoxP3+ T cells with inhibitory function (Treg) prevent the terminal effector cell differentiation in case of extreme immune activation, and potentiate immune memory. 5 often associated with a misbalanced differentiation of proinfl ammatory, effector and Treg cells, and disrupted Th1/Th2/Th17 cytokine balance. 6 The Bulgarian preparation Calgevax (BB-NCIPD Ltd) contains freeze-dried live bacteria derived from BCG culture. It is a potent stimulator of Th1 responses, and has been successfully applied for treatment of superfi cial bladder tumors, and malignant melanoma. 7 Data about the effects of BCG in HPV infection are still scarce. 8 We have applied for the fi rst time combined CO 2 microsurgery / Calgevax therapy in RRP patients that has resulted in a signifi cant reduction of relapses. 9 
AIM
The present study aims at delineating the characteristics of the ineffi cient cellular immune response in RRP, and investigates the effects of Calgevax (BCG) on the T cell response of patients subjected to combined surgery / immune modulation.
MATERIALS AND METHODS
RRP patients (n = 15, 9 men, 6 women, mean age 35.2 years) were subjected to CO 2 laser microsurgery followed by immunotherapy. Calgevax (2.56 х 10 8 CFU) was administered by scarifi cation (on a 25-cm² skin area) in 12 applications at 40-45-day intervals comprising a period of 18 to 20 months. The control group included age-and sex-matched healthy individuals fully conforming to the CLSI sta ndards. Informed consent approved by the local ethical committee was obtained from all participants. Immune parameters were defi ned before (0), 6, 12 and 20 months after the start of immune modulation. Percentages of peripheral blood lymphocyte subsets were studied by multicolor fl ow cytometry (FACSCanto II, BD), absolute counts were determined after a standard lysis-no-wash procedure using TRUCount tubes (BD Biosciences). Treg (CD4+CD25 hi +FoxP3+) were determined by FoxP3 intracellular staining (BD FoxP3 Staining Kit). Percentages of effector Tc1 (CD8+CD69+IFNγ+), Th1 (CD4+CD69+IFNγ+) and Th17 (CD4+CD69+IL-17+) cells were determined after overnight in vitro PHA stimulation and intracellular IFNγ staining. The in vitro PHA-stimulated secretion of IL-2, IL-4, IL-5, IL-10, IFNγ and TNFα was measured by fl ow cytometry (BD CBA kit). Intragroup and intergroup comparisons were performed with appropriate nonparametric statistical methods and software GraphPad, v. 5.
RESULTS
The baseline proportions and absolute counts of T (CD3+CD56-), B (CD19+CD3-) and NK (CD56+CD16+CD3-) cells in the patients group corresponded to the reference ranges for the Bulgarian population and did not change signifi cantly in the course of Calgevax treatment (data not shown). Further on, no signifi cant differences were detected for the CD4 (Fig. 1A ) and CD8 T subsets (Fig.  1B) as compared to healthy controls. Therefore, we looked for more subtle changes at the T cell subset level.
Signifi cantly increased levels of IFNγ-secreting CD4 (Th1) and CD8 (Tc1) cells were established in untreated RRP patients in response to nonspecific stimulation with PHA as compared to healthy controls (mean 9.3% vs. 5.7% and 15.7% vs. 8.4 %, respectively, p < 0.05 for both). After 20 months of Calgevax treatment Th1 levels were within control reference interval while high Tc1 levels persisted (Figs 2A, B) . Importantly, at 6 months of immunotherapy the share of Th17 cells signifi cantly decreased (0.4% vs. 0.7%), (Fig.  2C ) and at 12 months the level of circulating Treg cells signifi cantly increased as compared to baseline and healthy controls (8% vs. 4.5% and 3.8%, respectively). This increase was followed by normalization to control group levels at the end of the study period (Fig. 2D) .
To evaluate the functional consequences of the changes observed at the subset level, we studied the basic Th1 (IFNγ, TNFa, IL-2), Th2 (IL-4, IL-5) and regulatory (IL-10) cytokines secreted in response to non-specifi c stimulation. We found that IFNγ/IL-4 and IFNγ/IL-10 ratios characterizing the effective antiviral response, were signifi cantly reduced at baseline (58 vs. 139 and 15 vs. 26, respectively, p < 0.05 for both), but were restored to control levels (159 vs. 139 and 28 vs. 26, respectively, p > 0.05 for both) after 20 months of Calgevax application ( Figs 3A, B) .
DISCUSSION
Immune mechanisms that determine the manifestation and prognosis of chronic low-risk HPV infection are poorly understood. We studied RRP patients undergoing successful combined CO 2 laser microsurgery and Calgevax immunotherapy in order to explain the ineffi ciency of antiviral response and the mechanisms for its restoration. toxicity, phagocytosis, and antigen-specifi c response mediated by CD4 Th1 and cytotoxic CD8 (Tc1) Т lymphocytes. [9] [10] [11] In line with published data, 11 the background levels of the basic lymphocyte subsets in RRP patients revealed no apparent immune defi ciency. Further on, no signifi cant changes were detected for CD4 and CD8 T cells and their ratio, indicating more subtle defects.
Accumulating evidence from animal models and in vitro studies suggests that Th cell subsets are not irreversibly differentiated, but can exhibit plasticity by changing transcription factor expression or by expressing multiple transcription factors. This plasticity has been recently suggested to play a role in modulating immune response during infl ammation. 12 Our results show that RRP is associated with disturbed cytokine balance, characterized with predominance of Th17 and Th2 at the expense of Th1-type cytokines. The role of Th1 cytokines IFNg and IL-12 for the activation of natural cytotoxic mechanisms, the maturation of antigen-presenting dendritic cells and the effi cient activation and differentiation of adaptive anti-viral effectors is well established. 11, 13 Further on, the Th1 cytokine IL-2 is vital for the differentiation of Treg with inhibitory function that maintain an effectory / memory T cell balance in conditions of persistent immune stimulation as a hallmark of protective immune response. 5 On the other hand, a Th2-biased adaptive immune response has been reported in RRP. Both IL-10 and IL-4 are upregulated in papillomas and in peripheral blood mononuclear cells exposed to HPV-11 E6 protein, with a concomitant decrease of IFN-γ, IL-12 and IL-18 expression. This impaired cytokine balance correlates with disease severity. 14, 15 Besides, Th2-like chemokines CCL17, CCL18 and CCL22 were found to be elevated in RRP and reduced in concert with sustained clinical remission. 15 The role of Th17 in chronic viral infections remains controversial. Both protective and proinfl ammatory effects have been assigned to Th17 effectors, but there is growing evidence that Th17 cells are pathological in many human autoimmune and infl ammatory diseases, leading to intense interest in defi ning their origins, functions and developing strategies to block their pathological effects. [16] [17] [18] It has been demonstrated that the skewing of murine Th towards Th17 and Treg is mutually exclusive, the Th17/Treg balance being critical for immune homeostasis. 18, 19 Treg have been associated with both reduced antiviral T-cell responses, and with control of generalized T cell activation. 5 Our results suggest that BCG may benefi cially affect the differentiation and balance of the effector and regulatory T cell subsets in RRP patients by changing the cytokine background. In bladder cancer immunotherapy, BCG stimulation has been shown to elevate IL-2, TNF and INF-γ levels and activate Th1 cells necessary for cytotoxic T lymphocyte differentiation. 20 In our hands, Calgev ax potentiated the differentiation of Treg at the expense of proinfl ammatory Th17 cells. Importantly, Treg increase was temporary and did not limit cytotoxic CD8 response, as witnessed by high Tc1 levels and increased IFNγ/IL4 and IFNγ/IL10 ratios in the end of the study period. We may speculate that the actual effect of Treg is to limit the immune hyperactivation, prevent the depletion of virusspecifi c CD8 and CD4 T cell clones and potentiate the formation of virus-specifi c memory.
CONCLUSIONS
RRP is characterized with prevalence of Th17 and Th2 at the expense of Th1-type cytokines. BCG increases the effi ciency of antiviral T-cell response by restoring Th1/Th2/Th17 cytokine balance and inducing the differentiation of Treg. The latter prevent the exhaustion of effector clones in the settings of chronic infection and promote the development of protective T cell immune response.
